WELL Provides Corporate Update on Financial Performance of Acquired Canadian Clinics and Confirms Favourable Positioning Amidst Escalation of Tariffs between the US and Canada

Core Insights - WELL Health Technologies Corp. is focused on enhancing health outcomes through technology, with significant updates on financial performance, clinic acquisitions, and resilience against potential U.S.-Canada trade tariffs [1] Financial Performance - The company has implemented a technology-driven transformation strategy across its acquired clinics, resulting in increased efficiency and profitability [2] - Key performance metrics from the Canadian clinic M&A program show a significant improvement in ROIC, with figures of 41% for 2022, 24% for 2023, and 28% for 2024 [5] - The average acquisition multiple of adjusted EBITDA at purchase has decreased from 5.2x in 2022 to 3.5x in 2024, while the effective multiples at current run-rate are 2.0x, 2.3x, and 2.6x for the respective years [3][5] M&A Pipeline and Growth Outlook - WELL's M&A prospect pipeline currently includes 165 clinics generating over $440 million in annual revenue, with a near-term pipeline of 19 signed LOIs representing approximately $50 million in revenue [6][5] - The 2024 acquisition cohort is expected to contribute approximately the same amount of adjusted EBITDA as the combined 2022 and 2023 cohorts, marking it as the most EBITDA-additive year since 2021 [7][8] Resilience to Tariffs - The company has confirmed no exposure to U.S. tariffs on Canadian goods, and potential future tariffs on services would not impact operations as it does not engage in cross-border sales [9][10] - Over 60% of WELL's revenues, adjusted EBITDA, and cash flow are generated in U.S. dollars, positioning the company favorably against currency volatility [10][11]